To report blood pressure control in the Hypertension in the Very Elderly Trial, a placebo-controlled trial of hypertensive (systolic blood pressure (SBP) 160-199 mm Hg, diastolic blood pressure (DBP) o110 mm Hg) participants over the age of 80 years, given treatment in three steps: indapamide slow release 1.5 mg alone, indapamide plus 2 mg perindopril and indapamide plus 4 mg perindopril. The difference in control between participants with combined systolic and diastolic hypertension (SDH, DBPX90 mm Hg) and those with isolated systolic hypertension (ISH, DBPo90 mm Hg) is determined together with the effects of increments in the treatment regimen. At 2 years, the active treatment lowered blood pressure by 16.5/6.9 mm Hg more than that on placebo in participants with SDH and by 19.3/4.8 mm Hg more in those with ISH. The 2-year falls in pressure on placebo alone were 13.2/8.5 mm Hg in SDH and 8.2/1.5 mm Hg in ISH participants. With full titration of active treatment, 62% of SDH participants achieved goal SBP (o150 mm Hg) by 2 years and 71% of those with ISH. The corresponding results for DBP control (o80 mm Hg) were 40 and 78%. The addition of active perindopril 2 mg roughly doubled the percentage controlled, as did increasing to 4 from 2 mg. Blood pressure control was good with ISH and better than with SDH. The fall in SBP accounted for the observed 30% reduction in strokes, but the 21% reduction in total mortality and 64% reduction in heart failure were greater than predicted.
Introduction
The Hypertension in the Very Elderly Trial (HYVET) is a double-blind placebo-controlled trial of antihypertensive treatment in very elderly hypertensive patients over the age of 80 years. The main objectives of the trial were to identify any reduction in stroke events, and to relate this change and any change in total mortality, cardiac mortality and cardiovascular events to the difference in blood pressure between the groups.
Staessen et al. 1 have emphasised that any benefits of anti-hypertensive treatment are directly and closely related to the difference in blood pressure observed in the groups being compared. It is therefore of considerable importance to ensure that the size of the between-group difference in blood pressure is sufficient to produce any observed difference in events. We report the between-group difference in blood pressure in the HYVET and the extent to which goal blood pressure was achieved in both the actively treated and the placebo-treated groups. The between-group difference is also assessed in terms of the major outcomes of the trial, a 30% reduction in stroke events and a 21% reduction in total mortality. 2 
Subjects and methods
The protocol for the HYVET study and the outcomes have been published in detail. [2] [3] [4] In brief, after giving informed written consent, participants were given a placebo (matching 1.5 mg indapamide slow release (SR) tablets) and seen again after at least 1 month and again after at least 2 months. The sitting blood pressure after 1 and 2 months was measured twice after a rest of at least 5 min, to give four readings of sitting blood pressure. Participants were eligible for randomisation if the average of these systolic readings was 160-199 mm Hg and the diastolic readings was 90-109 mm Hg. In 2003, these requirements for both an elevated systolic and diastolic pressure (systolic and diastolic hypertension (SDH)) were dropped, and participants were also randomised with a diastolic pressure of o110 mm Hg provided systolic pressure was 160-199 mm Hg. If these subjects had a diastolic pressure o90 mm Hg, they were considered to have isolated systolic hypertension (ISH).
After at least 2 months on placebo, the standing blood pressure (taken twice) after 2 min standing was also requested and it was always recorded at subsequent visits. The standing blood pressure at the '2-month' visit did not influence randomisation, except that the standing systolic blood pressure had to be above or equal to 140 mm Hg, in order to exclude subjects with marked postural hypotension. Participants were randomised to 1.5 mg indapamide SR or matching placebo. The participants were then followed at 3, 6, 9 and 12 months, and 6 monthly thereafter. Participants were seen more frequently if considered clinically desirable. At any of these visits the treatment may have been increased to 1.5 mg indapamide SR plus 2 mg perindopril and then to 1.5 mg indapamide SR plus 4 mg perindopril (or matching placebos), with a view to obtaining a goal sitting systolic blood pressure of less than 150 mm Hg and a goal sitting diastolic blood pressure of less than 80 mm Hg.
Owing to the long duration of recruitment to the HYVET study, blood pressure control was examined by cohorts who have been studied over 1 or 2 years. Moreover, for those followed for 2 years, cohorts were identified who were receiving indapamide alone, indapamide plus 2 mg perindopril and indapamide plus 4 mg at the end of this period. Blood pressure control was examined at the end of indapamide (SR) monotherapy, where appropriate, indapamide plus 2 mg perindopril therapy and indapamide plus 4 mg perindopril treatment. A controlled blood pressure was one that had reached target blood pressure. Cases of systolic control (o150 mm Hg), diastolic control (o80 mm Hg) and both systolic and diastolic control are all reported. The corresponding analyses were also performed for the placebo medication.
As patients with ISH have, by definition, lower diastolic pressures, the analyses were performed separately for participants with SDH and those with ISH. Tables 1 and 2 give the average blood pressure results for 1-and 2-year cohorts of SDH and ISH participants. The results are also given in Figures 1a and b, which represent the results graphically and demonstrate how similar are the results for the 1-and 2-year cohorts for SDH, and the equivalent cohorts for ISH. The fall in systolic pressure for SDH was from an average baseline of 174 mm Hg, and from 171 mm Hg for ISH patients. For sitting systolic pressure, the placebo response in patients with SDH in the 1-year cohort was a fall of 15 mm Hg at 6 months, which remained at 1 year. The corresponding results for ISH participants were smaller at 9 mm Hg for 6 and 12 months, respectively. For the 2-year cohorts, the placebo fall averaged 14 and remained at 13 mm Hg at 18 and 24 months for SDH subjects, and 9 and 8 mm Hg for the corresponding figures for ISH patients. The response to active treatment was much greater than the placebo response (Table 3) . For SDH participants, and the 1-year cohort, the average fall with active treatment was 23.8 mm Hg, and remained at 27.0 mm Hg at Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.
Results

Systolic pressure
Blood pressure control in HYVET 12 months. The falls in actively treated participants with ISH were similar to these at 19.8 and 24.7 mm Hg at 6 and 12 months, respectively. For the 2-year cohorts, the fall in systolic pressure at 18 months was 29 mm Hg in both participants with SDH and ISH. After 2 years, the falls remained similar at 29.7 mm Hg in SDH and 27.5 mm Hg in participants with ISH (Table 3) . The results for the standing systolic pressures were similar to those of sitting pressure for both SDH and ISH patients. (Tables 1 and 2 ).
Diastolic pressure
Both the sitting and standing diastolic pressures fell with placebo by a similar amount after 6 and 12 months in subjects with SDH (8.2 and 7.8 mm Hg, respectively) in both positions (1-year cohort). In subjects with ISH, the diastolic falls were only 1-2 mm Hg in the sitting and standing positions. With active treatment in SDH, the sitting diastolic falls were 13.0 mm Hg (6 months) and remained at 14.7 mm Hg at 12 months (Tables 1 and 2) (1-year cohort). For ISH subjects, the sitting diastolic falls with active treatment were 5.1 mm Hg at 6 months and 6.4 mm Hg at 12 months (1-year cohort). The 2-year cohorts showed that placebo treatment was associated with an 8 mm Hg fall in diastolic pressure in SDH at 18 and 24 months, and for both sitting and standing pressures. In ISH, the corresponding falls were 1-2 mm Hg with placebo. For active treatment, the falls were 15 mm Hg in the SDH group and 6-7 mm Hg in the ISH group. Table 3 gives the response to active treatment not only before but also after adjusting for the fall on placebo. The fall in blood pressure tended to increase over 24 months in subjects with SDH and ISH. The treatment effect, adjusted for placebo fall, was a decrease in systolic sitting pressure of 15-17 mm Hg after 18-24 months in subjects with SDH and 19-20 mm Hg after 18-24 months in those with ISH. Similarly, the response of placebo-adjusted standing systolic tended to be lower in SDH patients (15-16 mm Hg) than ISH patients (19-20 mm Hg). It must be remembered that before adjustment for placebo response, the falls in sitting and standing systolic pressures were greater in SDH than ISH participants. The placebo-adjusted fall in diastolic pressure at 18-24 months on active treatment was marginally greater in those with SDH (7 mm Hg) than with ISH (5-6 mm Hg).
The response to active treatment was expected to vary according to the amount of active treatment prescribed. However, a decision to increase medication will depend on the blood pressure achieved with the previous level of medication. This level of pressure will also depend on the height of the untreated pressure. Moreover, although all investigators were required to achieve a systolic pressure of less than 150 mm Hg and a diastolic pressure o80 mm Hg (or titrate fully to active or placebo indapamide plus 4 mg perindopril), they varied in when and at what blood pressure level they made their decision to up-titrate. In view of these problems, Table 4 gives the degree of blood pressure control according to final treatment at 2 years. For each final treatment, the blood pressure control in participants with SDH is given after indapamide monotherapy (current or previous), after indapamide plus perindopril 2 mg (current or previous) and after indapamide plus perindopril 4 mg (current). A proportion of participants (14-18%) were up-titrated quickly from 2 to 4 mg perindopril, and had no record of a blood pressure on 2 mg perindopril. The first three columns consider those receiving active treatment, and the first column considers the percentage at goal blood pressure at 2 years when no increase in medication had been attempted. As would be expected, 46% (both goal systolic blood pressure (SBP) and goal diastolic Blood pressure control in HYVET CJ Bulpitt et al blood pressure (DBP) achieved) of those who stayed on monotherapy had been controlled on monotherapy. In contrast, column 3 indicates that 33% of those eventually titrated to indapamide plus 4 mg perindopril had reached goal BP at 2 years, but at the end of previous monotherapy only 5.7% had been controlled. Placebo treatment controlled pressure poorly, 32% of the 78 who remained on monotherapy were controlled for both SBP and DBP. The majority of placebo-treated participants were fully titrated, but only 4.8% reached goal blood pressure. For SDH participants, it appeared easier to reach a systolic goal of o150 mm Hg than a diastolic goal of o80 mm Hg. Table 5 gives the results for participants with ISH. With active treatment, systolic blood pressure control was achieved in a similar proportion to those with SDH when fully titrated (71% compared with 62%). However, as would be expected, diastolic blood pressure was better controlled in those with ISH (78 against 40%). Similarly, placebo treatment in ISH subjects controlled diastolic pressure in between 44 and 53% of the patients. However, full titration of placebo controlled both systolic and diastolic pressure only in 11% (5% in SDH) of the patients.
Discussion
The response to treatment with indapamide SR 1.5 mg ± perindopril 2-4 mg agrees well with the results of other trials in the elderly. Two trials in ISH subjects, the SHEP and Syst-Eur trials, reduced systolic pressure by 10-12 mm Hg and diastolic pressure by 4-5 mm Hg 5,6 compared with placebo. Within the HYVET, sitting systolic pressure at 2 years, after adjustment for placebo response, was reduced by 19.3 mm Hg in ISH and 17.0 mm Hg in SDH, and diastolic pressure was reduced by about up to 2 mm Hg less in ISH than in SDH participants. Similar results, both systolic and diastolic falls were observed for standing pressures. However, the results, unadjusted for placebo response, showed an average fall in SBP at 2 years on active treatment of 30.2 mm Hg in SDH and 27.5 mm Hg in ISH. These data do not suggest a greater efficacy of indapamide in ISH compared with SDH, although this was suggested when indapamide was compared with either amlodipine or hydrochlorothiazide. 7 The reduction in pressure compared with placebo in SDH participants was 16/7 mm Hg. This tended to be lower than in some previous trials. For example, the falls in SDH participants (adjusted for placebo effect) were 22/8 mm Hg in the European Working Party on Hypertension in the Elderly (EWPHE 8 ), 22/10 mm Hg in the STOP hypertension trial, 9 19/10 mm Hg in the Coope and Warrender trial 10 and 16/7 mm Hg in the MRC trial that included participants with ISH. 11 The fall in blood pressure in the placebo group at 2 years was 13/9 mm Hg in SDH participants and 8/2 mm Hg in ISH participants. These results agree Abbreviations: BP, blood pressure; DBP, diastolic BP; Ind, indapamide; SBP, systolic BP; P, perindopril.
Step 1, monotherapy with indapamide slow release (SR) 1.5 mg (or placebo), step 2 indapamide+2 mg perindopril, step 3 indapamide+4 mg perindopril. SBP control o150 mm Hg, DBP control o80 mm Hg. The great majority of the participants entering the HYVET had sustained hypertension. For SDH, of the 546 in Table 4 who received placebo at 2 years, only 78 (14%) were on placebo monotherapy and of these 78 only 32% had both SBP and DBP controlled. For active treatment, 46% of 167 had both systolic and diastolic control on 2 years of monotherapy. Similarly, less than 30% on placebo indapamide plus 2 mg perindopril were fully controlled at 2 years and full placebo titration only controlled 4.8%. In total, about 12% of SDH participants were controlled by placebo treatment at 2 years. When examining the blood pressure control in those with SDH who were fully titrated with active treatment at 2 years, we can see why this group had to be fully titrated as only 5.7% of these participants were controlled on monotherapy, 12.2% were controlled when an additional 2 mg perindopril was given and finally 33% were fully controlled when 4 mg perindopril was given. In contrast, those remaining on monotherapy at 2 years had 46% full control and 89% had control of systolic pressure, which is presumably why the investigator did not consider it necessary to titrate further. In total, about 39% of SDH participants were fully controlled at 2 years. However, 75% had systolic control and only 45% had diastolic control.
For ISH participants, control with active treatment was more satisfactory. Full control was achieved in 62% of all the ISH participants, systolic control in 73% and diastolic control in 77%. The treatment increments would appear sensible and efficacious in the very elderly hypertensive.
Three meta-regressions have been published from the recent Blood Pressure Lowering Treatment Trialists Collaboration study of the effect of treatment on events in older adults over 70 years of age. 12, 13 The systolic reduction in the HYVET of 18 mm Hg when entered in the meta-regression gave an expected reduction of 30.2% for stroke, which agrees almost exactly with our report of a 30% reduction. However, for total mortality, the HYVET results (a fall of 21%) greatly exceeded the expected increase of 9%, and the observed 64% reduction in heart failure was much greater than the expected 27%. These greater benefits may be due to unknown properties of indapamide SR or perindopril in terms of producing a more favourable blood pressure profile, or for total mortality, the fact that older trials often employed higher doses of diuretic with instant rather than sustained release properties. Sustained release technology may reduce peak drug concentrations and adverse consequences such as potassium loss. In the case of heart failure, a diuretic plus an ACE inhibitor may simply be a most suitable combination little used in the older trials. Abbreviations: BP, blood pressure; DBP, diastolic BP; Ind, indapamide; SBP, systolic BP; P, perindopril.
Step 1, monotherapy with indapamide slow release (SR) 1.5 mg (or placebo), step 2 indapamide+2 mg perindopril, step 3 indapamide+4 mg perindopril. SBP control o150 mm Hg, DBP control o80 mm Hg. Blood pressure control in HYVET CJ Bulpitt et al
Conclusion
In the HYVET study, active treatment (indapamide SR 1.5 mg ± perindopril 2-4 mg) produced a fall of 17 mm Hg systolic and 7 mm Hg diastolic compared with placebo in participants with SDH. In participants with ISH, the average placebo adjusted fall at two years in systolic pressure (19.3 mm Hg) tended to be slightly greater than those with SDH, and the falls in diastolic pressure tended to be 2 mm Hg greater in those with SDH rather than ISH. The placebo responses were in agreement with those observed in similar trials in the elderly, with only small falls (1-2 mm Hg) in diastolic pressure in participants with ISH. Blood pressure control was good with ISH and better than with SDH. The 30% reduction in strokes observed with active treatment was to be expected from the observed falls in systolic pressure. However, the falls in total mortality and heart failure were greater than expected.
Future research in this age group may wish to take account of the presence of SDH or ISH when assessing blood pressure control.
